These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 3496938

  • 1. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF.
    Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH.
    Brain Res; 1987 Jul 14; 415(2):293-9. PubMed ID: 3496938
    [Abstract] [Full Text] [Related]

  • 2. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum.
    Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH.
    Life Sci; 1987 Jan 12; 40(2):193-202. PubMed ID: 3491946
    [Abstract] [Full Text] [Related]

  • 3. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice.
    Heikkila RE, Cabbat FS, Manzino L, Duvoisin RC.
    Neuropharmacology; 1984 Jun 12; 23(6):711-3. PubMed ID: 6611514
    [Abstract] [Full Text] [Related]

  • 4. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Sirinathsinghji DJ, Whittington PE, Audsley AR.
    Brain Res; 1986 Dec 10; 399(2):339-45. PubMed ID: 2435361
    [Abstract] [Full Text] [Related]

  • 5. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
    Elsworth JD, Taylor JR, Sladek JR, Collier TJ, Redmond DE, Roth RH.
    Neuroscience; 2000 Dec 10; 95(2):399-408. PubMed ID: 10658619
    [Abstract] [Full Text] [Related]

  • 6. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
    Pifl C, Schingnitz G, Hornykiewicz O.
    Neurosci Lett; 1988 Oct 05; 92(2):228-33. PubMed ID: 3263594
    [Abstract] [Full Text] [Related]

  • 7. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
    Di Paolo T, Bédard P, Daigle M, Boucher R.
    Brain Res; 1986 Aug 06; 379(2):286-93. PubMed ID: 2427166
    [Abstract] [Full Text] [Related]

  • 8. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
    Sershen H, Hashim A, Lajtha A.
    Pharmacol Biochem Behav; 1987 Oct 06; 28(2):299-303. PubMed ID: 3500479
    [Abstract] [Full Text] [Related]

  • 9. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
    Pérez-Otaño I, Oset C, Luquin MR, Herrero MT, Obeso JA, Del Río J.
    Neurosci Lett; 1994 Jul 04; 175(1-2):121-5. PubMed ID: 7970192
    [Abstract] [Full Text] [Related]

  • 10. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
    Elsworth JD, Deutch AY, Redmond DE, Taylor JR, Sladek JR, Roth RH.
    Neuroscience; 1989 Jul 04; 33(2):323-31. PubMed ID: 2622529
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
    Bradbury AJ, Costall B, Domeney AM, Testa B, Jenner PG, Marsden CD, Naylor RJ.
    Neurosci Lett; 1985 Oct 24; 61(1-2):121-6. PubMed ID: 2417166
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice. Antagonism by monoamine oxidase inhibitors.
    Bradbury AJ, Costall B, Jenner PG, Kelly ME, Marsden CD, Naylor RJ.
    Neuropharmacology; 1986 Aug 24; 25(8):897-904. PubMed ID: 3022182
    [Abstract] [Full Text] [Related]

  • 16. Increase of striatal dopamine turnover by stress in MPTP-treated mice.
    Urakami K, Masaki N, Shimoda K, Nishikawa S, Takahashi K.
    Clin Neuropharmacol; 1988 Aug 24; 11(4):360-8. PubMed ID: 3264755
    [Abstract] [Full Text] [Related]

  • 17. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
    Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR.
    Neurosci Lett; 1985 Oct 24; 61(1-2):195-200. PubMed ID: 3878482
    [Abstract] [Full Text] [Related]

  • 18. Behavioral and biochemical changes following acute administration of MPTP and MPP+.
    Tadano T, Satoh N, Sakuma I, Matsumura T, Kisara K, Arai Y, Kinemuchi H.
    Life Sci; 1987 Mar 30; 40(13):1309-18. PubMed ID: 2436017
    [Abstract] [Full Text] [Related]

  • 19. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
    Sirinathsinghji DJ, Heavens RP, McBride CS.
    Brain Res; 1988 Mar 08; 443(1-2):101-16. PubMed ID: 3258784
    [Abstract] [Full Text] [Related]

  • 20. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.
    Falardeau P, Bédard PJ, Di Paolo T.
    Neurosci Lett; 1988 Mar 31; 86(2):225-9. PubMed ID: 2966905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.